Regulatory T Cell Therapy
Our group manufactures Regulatory T Cells for clinical trials in patients who have received solid organ transplant or who have been diagnosed with an autoimmune disease such as diabetes. Our team tests the safety and efficacy of these cells in order to prevent solid organ rejection or to improve symptoms of autoimmune disease.
Regulatory T cells are a subset of T cells that have anti-inflammatory properties. In animal models, they have the ability to prevent rejection of allografts (tissue from another, genetically distinct animal) and to ameliorate the symptoms of autoimmune disease. While these cellular therapy products are investigational new drugs and limited by federal law, we envision their use by patients in the future.